Literature DB >> 7012932

Stability of prostaglandin I2 in human blood.

D D Pifer, L M Cagen, C M Chesney.   

Abstract

Prostaglandin I2 (PGI2) is hydrolyzed more slowly in human plasma than in buffer at the same pH; this stabilization appears to be due to binding of PGI2 to albumin. The stability of the antiaggregatory potency of PGI2 is similar in human blood and in plasma buffered to pH 7.55. No measurable conversion of [3H]-PGI2 to radioactive or nonradioactive metabolites occurred during incubation with blood.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7012932     DOI： 10.1016/0090-6980(81)90135-0

Source DB:  PubMed          Journal:  Prostaglandins        ISSN： 0090-6980


  5 in total

1.  Subcellular localization and secretion of factor V from human platelets.

Authors:  C M Chesney; D Pifer; R W Colman
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

2.  Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (Apo A-I). A novel function of Apo A-I.

Authors:  Y Yui; T Aoyama; H Morishita; M Takahashi; Y Takatsu; C Kawai
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

3.  Comparison of the effect of a conventional heparin and a low molecular weight heparinoid on platelet function.

Authors:  D P Mikhailidis; M A Barradas; A M Mikhailidis; H Magnani; P Dandona
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

4.  Serum prostacyclin binding defects in thrombotic thrombocytopenic purpura.

Authors:  K K Wu; E R Hall; E C Rossi; A C Papp
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

5.  Evaluation of the stability, bioavailability, and hypersensitivity of the omega-3 derived anti-leukemic prostaglandin: Δ(12)-prostaglandin J3.

Authors:  Avinash K Kudva; Naveen Kaushal; Sonia Mohinta; Mary J Kennett; Avery August; Robert F Paulson; K Sandeep Prabhu
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.